Glia-Targeted Therapeutics

Despite remarkable advances in glial biology, the development of effective glia-targeted therapeutics has lagged behind. Accumulating evidence has established glial cells as dynamic regulators of neuroimmune communication, synaptic function, metabolic homeostasis, tissue repair, and disease progression. Advances in single-cell and spatial transcriptomics, molecular profiling, functional imaging, and human-relevant experimental models have revealed remarkable diversity among central and peripheral glial populations, highlighting context-dependent functional states and complex communication networks involving neurons, vascular cells, immune cells, and other glia. These discoveries have expanded therapeutic opportunities while challenging conventional pharmacological strategies that broadly target individual glial cell types or isolated inflammatory pathways. Although numerous pharmacological interventions intentionally or unintentionally modulate glial function, clinical translation has remained limited, highlighting the need for a more integrated therapeutic framework. In this perspective, we critically examine the current landscape of glia-targeted therapeutics through the concept of glial pharmacology, presented as a conceptual framework for understanding how pharmacological interventions modulate glial cells, their functional states, and multicellular communication networks to influence nervous system homeostasis and disease. Rather than providing an exhaustive review, we synthesize the lessons learned from existing therapeutic strategies, discuss the major biological and translational challenges limiting clinical success, and propose guiding principles for the rational development of next-generation glia-targeted therapeutics. We argue that future progress will depend on moving beyond broad cell-specific modulation toward context-dependent therapeutic strategies informed by glial biology, multicellular communication networks, biomarker-guided target engagement, and disease context.